Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C3TI
|
|||
| Former ID |
DIB014522
|
|||
| Drug Name |
Resimmune
|
|||
| Synonyms |
A-dmDT390-bisFv immunotoxin
Click to Show/Hide
|
|||
| Indication | Cutaneous T-cell lymphoma [ICD-11: 2B01; ICD-10: C84.8; ICD-9: 202.1, 202.2] | Phase 2 | [1], [2], [3], [4] | |
| Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 1/2 | [5] | ||
| Company |
Angimmune
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | T-cell surface glycoprotein CD3 epsilon (CD3E) | Target Info | Modulator | [6] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| T cell receptor signaling pathway | ||||
| Chagas disease (American trypanosomiasis) | ||||
| Measles | ||||
| HTLV-I infection | ||||
| Primary immunodeficiency | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Leptin Signaling Pathway | ||||
| Panther Pathway | T cell activation | |||
| Pathway Interaction Database | TCR signaling in naï | |||
| IL12-mediated signaling events | ||||
| TCR signaling in naï | ||||
| CXCR4-mediated signaling events | ||||
| IL23-mediated signaling events | ||||
| Downstream signaling in naï | ||||
| IL12 signaling mediated by STAT4 | ||||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| Phosphorylation of CD3 and TCR zeta chains | ||||
| Translocation of ZAP-70 to Immunological synapse | ||||
| Generation of second messenger molecules | ||||
| PD-1 signaling | ||||
| WikiPathways | TCR Signaling Pathway | |||
| TCR signaling | ||||
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | ||||
| Costimulation by the CD28 family | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038158) | |||
| REF 6 | Resimmune, an anti-CD3 recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma.Haematologica.2015 Jun;100(6):794-800. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.